IL-33 Targeting Shows Promise in COPD Treatment
Recent studies highlight IL-33 inhibition as a promising approach to reduce exacerbations in COPD patients. Tozorakimab, an IL-33 inhibitor, is poised to impact the COPD market by addressing inflammation and mucus plugs. Experts like Dr. Francesca Polverino discuss the dual role of IL-33 in COPD, emphasizing both benefits and remaining unknowns in treatment outcomes.
HCPLive·



